
|Videos|October 6, 2017
What Were the Top-line Data Results from the LEAP-1 Study?
Author(s)Contagion® Editorial Staff
Steven Gelone, PharmD, shares the topline data yielded from the LEAP-1 study.
Advertisement
Steven Gelone, PharmD, chief scientific officer at Nabriva Therapeutics, shares the topline data yielded from the LEAP-1 study.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Is 4 Weeks of Glecaprevir/Pibrentasvir Sufficient to Treat Early Hepatitis C Infection?
2
Antibiotic Shows Promise in Treating Gram-Positive Pneumonia, Including in High-Risk Patients
3
Vaccines as a Secondary Strategy in the Fight Against Antimicrobial Resistance
4